Table 3.
Comparison of the prescription of anticoagulants in primary prevention and secondary prevention of stroke
| Primary prevention | Secondary prevention | |||||
|---|---|---|---|---|---|---|
| Characteristics |
Total N = 2100 Characteristics of the sample (%) |
Prevalence within subgroup (%) |
Total N = 1065 Characteristics of the sample (%)/Mean(± SD) |
Prevalence within subgroup (%) |
||
| No Anti. N = 1432 | Anti. N = 668 | No Anti. N = 706 |
Anti N = 359 |
|||
| Age, N(%)***### | ||||||
| 80–84 | 1137(54.1) | 724(50.6) | 413(61.8) | 451(42.3) | 253(35.8) | 198(55.2) |
| 85–89 | 701(33.4) | 496(34.6) | 205(30.7) | 382(35.9) | 265(37.5) | 117(32.6) |
| 90 + | 262(12.5) | 212(14.8) | 50(7.5) | 232(21.8) | 188(26.6) | 44(12.3) |
| Sex, Female, N(%)***### | 901(42.9) | 574(40.1) | 327(49) | 440(41.3) | 263(37.3) | 177(49.3) |
| Clinical department***### | ||||||
| Cardiology, N(%) | 679(32.3) | 335(23.4) | 344(51.5) | 107(10) | 48(6.8) | 59(16.4) |
| Geriatrics, N(%) | 619(29.5) | 458(32) | 161(24.1) | 510(47.9) | 376(53.3) | 134(37.3) |
| Neurology, N(%) | 46(2.2) | 30(2.1) | 16(2.4) | 265(24.9) | 139(19.7) | 126(35.1) |
| Others, N(%) | 756(36) | 609(42.5) | 147(22) | 183(17.2) | 143(20.3) | 40(11.1) |
| Year, N(%)***### | ||||||
| 2016–2017 | 497(23.7) | 397(27.7) | 100(15) | 225(21.1) | 174(24.6) | 51(14.2) |
| 2017–2018 | 567(27) | 396(27.7) | 171(25.6) | 259(24.3) | 193(27.3) | 66(18.4) |
| 2018–2019 | 552(26.3) | 354(24.7) | 198(29.6) | 299(28.1) | 194(27.5) | 105(29.2) |
| 2019–2020 | 484(23) | 285(19.9) | 199(29.8) | 282(26.5) | 145(20.5) | 137(38.2) |
| HAS-BLED Score,N(%)**## | ||||||
| HAS-BLED Score < 3 | 297(14.1) | 197(13.8) | 100(15) | 11(1) | 8(1.1) | 3(0.8) |
| 3 < = HAS- BLED Score < = 4 | 1386(66) | 920(64.2) | 466(69.8) | 385(36.2) | 228(32.3) | 157(43.7) |
| HAS- BLED Score > = 5 | 417(19.9) | 315(22) | 102(15.3) | 669(62.8) | 470(66.6) | 199(55.4) |
| Use of APT, Y, N(%)***### | 808(38.5) | 593(41.4) | 215(32.2) | 584(54.8) | 435(61.6) | 149(41.5) |
| Dementia, Y, N(%)**### | 115(5.5) | 93(6.5) | 22(3.3) | 168(15.8) | 136(19.3) | 32(8.9) |
Primary prevention, ***p < 0.001, **p < 0.01, *p < 0.05 for comparison of anticoagulation status (anticoagulation, no anticoagulation) within each variable
Secondary prevention, ###p < 0.001, ##p < 0.01, #p < 0.05 for comparison of anticoagulation status (anticoagulation, no anticoagulation) within each variable